Архиви на јавното здравје

Том. 15 Бр. 2 (2023): Arch Pub Health
Јавно здравје

Quality of life in patients with vitiligo in North Macedonia

Online First (English) pdf 18-26 (English)
  • Наташа Теовска-Митревска
Наташа Теовска-Митревска
Општа болница „Ремедика“, Оддел за дерматологија, Скопје, Северна Македонија
ДОИ: https://doi.org/10.3889/aph.2023.6108

Објавено 2023-11-20

Клучни зборови

  • витилиго,
  • индекс на квалитет на живот,
  • псориаза,
  • алопеција ареата,
  • индекс за мерење на површината на телото

Како да се цитира

1.
Теовска-Митревска Н. Quality of life in patients with vitiligo in North Macedonia . Arch Pub Health [Internet]. 2023 Nov. 20 [cited 2024 Jul. 16];15(2). Available from: https://id-press.eu/aph/article/view/6108

Авторско право(c) 2023 Natasa Teovska-Mitrevska

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Апстракт

Vitiligo is an acquired depigmentation deficit with a high prevalence, ranging from 0.5% to 7.8%. The aim of the study was to measure the quality of life (QL) of patients with vitiligo, expressed through the Dermatological Quality of Life Index (DLQI). Materials and methods: This cross-sectional study was realized in a period of 1 year. Two questionnaires were used in the study. Тhe first questionnaire contains data from the DLQI, designed for use in adults over 16 years of age, taken from the Cardiff University in the UK. The second questionnaire contains demographic and clinical characteristics of patients (age, gender, place of residence, marital status, education), activity, comorbid diseases and BMI, age at onset, site of onset of lesions, duration of disease, family history, type, activity, natural course, body mass index (BMI) and therapy. Results: Among 71 subjects included in the study, the total score of the DLQI ranged from 0 to 28 (from a maximum of 30 points), and the average was 11.70 ± 5.7. Female patients had greater QL impairment (total mean value of 8.03) than men (5.99); there was a statistically significant difference between  both sexes (P = 0.019). The total score of QL in terms of symptoms related to the condition in the six domains strongly affected QL of 45.1% of patients. The QL was significantly worse in the studied group of 16-30 years (13.85 ± 5.3) compared to the population of 51-60 and over 60 years (6.75 ± 5.7, and 7.0 ± 2.3). As the age of patients advanced, the QL improved. Subjects with higher education had a higher score (14.41 ± 6.6; p=0.001). Conclusion: Female patients with vitiligo have impaired QL in comparison to male. With age, the QL in patients with vitiligo improves. Patients with a lower degree of education have a better QL

Online First (English) pdf 18-26 (English)

Downloads

Download data is not yet available.

Референци

  1. The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998; 46(12):1569-85.DOI:10.1016/s0277-9536(98)00009-4 DOI: https://doi.org/10.1016/S0277-9536(98)00009-4
  2. Rosenberg M. Conceiving the Self. New York: Basic Books.1979.doi.org/10.2307/3340091
  3. Taïeb A. The definition and assessment of vitiligo: A consensus report of the Vitiligo European Task Force, Pigment Cell Research. 2007;20(1):27 – 35.DOI:10.1111/j.1600-0749.2006.00355.x DOI: https://doi.org/10.1111/j.1600-0749.2006.00355.x
  4. Taïeb A. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25(3): E1-13. DOI: 10.1111/j.1755-148X.2012.00997.x DOI: https://doi.org/10.1111/j.1755-148X.2011.00939.x
  5. Hongbo Y, Thomas CL, Harrison MA, SalekMS, FinlayAY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005;125:659–664. DOI:10.1111/j.0022-202X.2005.23621.x DOI: https://doi.org/10.1111/j.0022-202X.2005.23621.x
  6. Kent G, Al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol.1996;21:330–333. doi.org/10.1111/j.1365-2230.1996.tb00116.x DOI: https://doi.org/10.1046/j.1365-2230.1996.d01-219.x
  7. Parsad D, Dogra S,Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes 2003;1:58. DOI:10.1186/1477-7525-1-58 DOI: https://doi.org/10.1186/1477-7525-1-58
  8. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY: DLQI scores in vitiligo: reliabilityand validity of the Persian version. BMC Dermatol2004;4:8.doi:10.1186/1471-5945-4-8 DOI: https://doi.org/10.1186/1471-5945-4-8
  9. Ongenae K, van Geel N, De Schepper S, Nae-yaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005;152:1165–1172. DOI:10.1111/j.13652133.2005.06456.x DOI: https://doi.org/10.1111/j.1365-2133.2005.06456.x
  10. Ongenae K, Dierckxsens L, Brochez L, vanGeel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo paients and effect of the use of camouflage. Dermatology 2005;210:279–285. DOI:10.1159/000084751 DOI: https://doi.org/10.1159/000084751
  11. Mechri A,Amri M, Douarika AA,Ali Hichem BH, Zouari B, Zili J. Psychiatric morbidity and quality of life in vitiligo: a case controlled study. Tunis Med 2006;84:632–635. DOI: 10.17354/ijss/2015/461
  12. Van Geel N, Ongenae K, Vander Heghen Y, Vervaet C, Naeyaert JM. Subjective and objective evaluation of noncultured epidermal cel-lular grafting for repigmenting vitiligo. Dermatology 2006; 213:23–29. DOI:10.1159/000092833 DOI: https://doi.org/10.1159/000092833
  13. Belhadjali H, Amri M, Mecheri A, Doarika A, Khorchani H, Youssef M et al. Vitiligo and quality of life: a case-control study. Ann Dermatol Venereol 2007;134:233–236. DOI:10.1016/s0151-9638(07)91814-1 DOI: https://doi.org/10.1016/S0151-9638(07)91814-1
  14. Al Robaee AA. Assessment o fquality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia. Saudi Med J 2007;28:1414–1417. doi: 10.15537/smj.2021.42.6.20200833 DOI: https://doi.org/10.15537/smj.2021.42.6.20200833
  15. Dolatshahi M, Ghazi P,Feizy V, Hemami MR. Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran. Indian J Dermatol Venereol Leprol 2008;74:700. DOI:10.4103/0378-6323.45141 DOI: https://doi.org/10.4103/0378-6323.45141
  16. Kostopoulou P, Jouary T, Quintard B, Ezze-dine K, MarquesS, Boutchnei S,Taieb A. Objective vs subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Br J Dermatol 2009;161:128–133. DOI:10.1111/j.1365-2133.2009.09077.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09077.x
  17. Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M: Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009;161:134–139. DOI:10.1111/j.1365-2133.2009.09091.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09091.x
  18. Mashayekhi V, Javidi Z, Kiafar B, Manteghi AA, Saadatian V, Esmaeili HA, Hosseinaliza-deh S. Quality of life in patients with vitiligo: a descriptive study on 83 patients attending a PUVA therapy unit in Imam Reza Hospital, Mashad. Indian J Dermatol Venereol Leprol 2010;76:592. DOI:10.4103/0378-6323.69097 DOI: https://doi.org/10.4103/0378-6323.69097
  19. Wang KY, Wang KH, Zhang ZP. Health-re-lated quality of life and marital quality of vitiligo patients in China. J Eur Acad DermatolVenereol 2011;25:429–435. DOI:10.1111/j.1468-3083.2010.03808.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03808.x
  20. Chan MF, Chua TL,Goh BK, Aw CW, Thng TG, Lee SM. Investigating factors associated with depression of vitiligo patients in Singapore. J Clin Nurs 2011;21:1614–1621 DOI:10.1111/j.1365-2702.2011.03777.x DOI: https://doi.org/10.1111/j.1365-2702.2011.03777.x
  21. Wong S, Bao MBBCH, Baba R. Quality of life among Malaysian patients with vitiligo. Int J Dermatol 2012;51:156–161. doi.org/10.1159/000448656 DOI: https://doi.org/10.1111/j.1365-4632.2011.04932.x
  22. Ingordo V, Cazzaniga S, Gentile C, Iannaz-zone SS, CusanoF, Naldi L. Dermatology Life Quality Index score in vitiligo patients: a pilot study among young Italian males. G Ital Dermatol Venereol 2012;147:83–90. doi.org/10.1159/000363407
  23. Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life. JAMA Dermatol 2013; 149:159–164. DOI:10.1001/jamadermatol.2013.927 DOI: https://doi.org/10.1001/jamadermatol.2013.927
  24. Kiprono S, Chaula B, Makwaya C, Naafs B, Masenga J. Quality of life of patients with vitiligo attending the Regional Dermatology Training Center in Northern Tanzania. Int J Dermatol 2013;52:191–194. DOI:10.1111/j.1365-4632.2012.05600. DOI: https://doi.org/10.1111/j.1365-4632.2012.05600.x
  25. Karelson M, Silm H, Kingo K: Quality of life and emotional state in vitiligo in an Estonian sample: comparison with psoriasis and healthy controls. Acta DermVenereol 2013;93:446–450. DOI:10.2340/00015555-1520 DOI: https://doi.org/10.2340/00015555-1520
  26. Parsad D. Clinical and molecular aspects of vitiligo treatments. Int J Mol Sci 2018;19(5):1509. DOI: 10.3390/ijms19051509 DOI: https://doi.org/10.3390/ijms19051509
  27. Budania A, Parsad D, Kanwar AJ, Dogra S. Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study. Br J Dermatol 2012;167:1295–1301. DOI: 10.1111/bjd.12007 DOI: https://doi.org/10.1111/bjd.12007
  28. Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, Harris JE, Huggins RH, et al. International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. Br J Dermatol 2019;180(3):574–9. DOI:10.1111/bjd.17013 DOI: https://doi.org/10.1111/bjd.17013
  29. Christina B, Khaled E. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol 202;48(3):252-270. doi: 10.1111/1346-8138.15743 DOI: https://doi.org/10.1111/1346-8138.15743
  30. Batchelor JM, Gran S, Leighton P, Howells L, Montgomery AA. Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability. Br J Dermatol 2022;187(4):548-556. doi: 10.1111/bjd.21671. DOI: https://doi.org/10.1111/bjd.21671
  31. Pandya AG, Ezzedine K. Noticeability of vitiligo is in the eye of the beholder. Br J Dermatol 2022;187(4):461-462.oi: 10.1111/bjd.21779. DOI: https://doi.org/10.1111/bjd.21779
  32. Porter JR, Beuf AH, Lerner A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with "normal" control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol 1986;15(2 Pt 1):220-4.doi:10.1016/s0190-9622(86)70160-6 DOI: https://doi.org/10.1016/S0190-9622(86)70160-6
  33. Ghajarzadeh M, Ghiasi M, Kheirkhah S. Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata. Acta Med Iran. 2012;50(7):511-5. PMID: 22930385.